Futibatinib
Anogenital Cancer
Boundless Bio, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Anogenital Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bbi-825 Boundless Bio, Inc. | Phase 1 | CC |
Panobinostat Boundless Bio, Inc. | Phase 1 | CC |
Bbi-355 Boundless Bio, Inc. | Phase 1 | CC |
Same molecule, other indications
Futibatinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →